Thiakis

Novel hormone analogues for appetite suppression

Thiakis was founded in 2004 to develop novel analogues of naturally occurring hormones for the treatment of obesity and co-morbidities based on the research of Professor Steve Bloom.

CEO  John Burt

Advent Contact  Raj Parekh

Advent invested in the Series A in 2006. Thiakis was acquired by Wyeth in 2008 in a transaction worth up to $150m.
Exited Investments
18 December 2008 in Press Release, Thiakis

Wyeth Pharmaceuticals acquires Thiakis in a transaction worth up to £100m

Press Release.   London, December 18, 2008. Advent Venture Partners (‘Advent Ventures’) today announces the sale of one of its portfolio companies, Thiakis, to Wyeth Pharmaceuticals, a division of Wyeth…
Read More
12 March 2008 in Press Release, Thiakis

Novel therapy for treatment of obesity enters clinical trials

Press Release.   London, UK, 12 March 2008 – Thiakis Limited, the biopharmaceutical company focused on the development of peptide hormones for the treatment of obesity, announced today that it…
Read More